Project Grant R01CA300653
Award Date 9/3/26
Completion Date 8/31/30
Dollars Obligated $733K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90032, USA
Similar Awards
- The National Cancer Institute of the National Institutes of Health awarded the University of Southern California $426,828 on July 6, 2026, through the Cancer Cause and Prevention Research program (CFDA 93.393) to test regulatory strategies promoting e-cigarette cessation among young adults. The University of Southern California will conduct a study using a simulated vape shop experimental laboratory space ("The Puff Point") to evaluate two innovative policy interventions designed to...
- The National Institutes of Health National Cancer Institute awarded Cincinnati Children's Hospital Medical Center $694,182 on June 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a prospective longitudinal cohort study examining biomarker levels and respiratory health effects associated with exposure to electronic cigarettes and combustible cigarettes in young children. The research enrolls 300 children ages 1 to 10 years across three equal exposure...
- The National Cancer Institute awarded The Ohio State University $662,436 on August 14, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to design tiered tax rates for electronic cigarettes based on their appeals to youth and young adults. The project addresses evidence gaps in electronic cigarette taxation policy. Specifically, it examines how tiered excise taxes—which impose higher tax rates on electronic cigarettes with youth-appealing features such as flavor, product...
- The National Cancer Institute, an operating division of the Department of Health and Human Services, awarded Chapman University $649,603 on June 15, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct the TRAQ-TO-QUIT smoking cessation intervention study. The research combines three evidence-based approaches into a multilevel intervention: pediatrician-initiated brief advice and referral to cessation services; novel behavioral tele-counseling to guide smokers...
- The Department of Health and Human Services National Institutes of Health Office of the Director awarded $821,294 to The Trustees of Columbia University in the City of New York on September 1, 2026, under the Family Smoking Prevention and Tobacco Control Act Regulatory Research program (CFDA 93.077, Project Grant R01HL179303). The award funds the VAPESCAN study, a longitudinal investigation examining early lung toxicity associated with e-cigarette versus cigarette use in young adults aged 18–50....
- The National Institutes of Health National Cancer Institute awarded The Medical University of South Carolina $586,018 on July 10, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a three-arm clinical trial testing augmented doses of nicotine replacement therapy for individuals who use both combustible cigarettes and e-cigarettes and wish to quit both products. The trial will randomize dual-use participants to receive behavioral support combined with...
- Federal Grant Award Summary The National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded the University of Alabama a Project Grant of $2,524,071 on September 23, 2025, for research investigating the neurocomputational mechanisms underlying self-regulation and reinforcement learning in smoking cessation decisions. The four-year project, with completion scheduled for August 31, 2029, will employ computational model-based multimodal neuroimaging...
- The National Cancer Institute awarded the University of Southern California $699,303 on August 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to identify pre-diagnostic epigenetic biomarkers of colorectal cancer risk and understand epigenetic mechanisms of lifestyle and genetic CRC risk factors across multiple U.S. populations. The research will conduct a nested case-control study of 1,500 colorectal cancer cases and 1,500 matched controls drawn from the...
- The National Cancer Institute awarded the Board of Regents of the University of Nebraska, through its University of Nebraska Medical Center division, $948,630 under the Cancer Cause and Prevention Research program (CFDA 93.393) on August 1, 2026, for a naturalistic cohort study examining the real-world effectiveness of smoking cessation aids in US adults. The project will conduct a longitudinal survey study using the Understanding America Study, a nationally representative panel of 20,000 US...
- The National Cancer Institute awarded the University of Rochester $583,304 on August 13, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate toxicological assessment of emerging nicotine analogs in electronic nicotine delivery systems (ENDS). The research addresses a substantial knowledge gap regarding the safety profile of novel nicotine analogs, including 6-methyl nicotine and nicotinamide, which manufacturers have introduced to circumvent premarket...